Roche takes PPMS lead as Novartis's Gilenya fails
This article was originally published in Scrip
Executive Summary
Novartis's approved multiple sclerosis drug Gilenya (fingolimod) has failed in a Phase III study in primary progressive MS, a distinct, hard to treat subgroup of the disease affecting around 10% of all sufferers.